arrow
T

Takumi Kawaguchi

Kurume University School of Medicine
H指数:61
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Functional and body composition outcomes of pharmacological interventions for sarcopenia in older adults: A systematic review and pairwise meta-analysis of randomized controlled trials

老年人群肌少症药物干预的功能和身体成分结局:一项随机对照试验的系统综述和成对meta分析

2026-11-040
PRE
A microbiota-driven CCL25–CCR9 axis reprograms intestinal ILC2s in the distal small intestine to promote metabolic dysfunction in obesity

微生物组驱动的CCL25–CCR9轴通过重编程远端小肠的ILC2s来促进肥胖中的代谢功能障碍

2026-10-090
OAAI
Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

durvalumab联合tremelimumab治疗肝细胞癌患者淋巴细胞计数早期变化可预测临床结局

2026-10-070
OAAI
Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease

代谢负担和高尿酸血症与有无脂肪性肝病的个体中与CKD相关结局相关

2026-09-070
PRE
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

代谢功能障碍相关脂肪性肝病(MASLD)2026年循证临床实践指南

2026-05-120
OAAI
Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort

评估影响肝癌患者甲胎蛋白水平因素的大型多中心队列研究

2026-04-300
PRE
Dynamic Risk Modelling of Hepatocellular Carcinoma

肝癌动态风险建模

2026-04-120
PRE
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report

恶性肝细胞肿瘤(Not Otherwise Specified)经新FP疗法后行转化性肝切除术:一例病例报告

2026-02-240
PRE
Guidance for Liver Rehabilitation in Chronic Liver Disease

慢性肝病肝脏康复指导

2026-01-310
OAAI
The Usefulness of Short-Type Single Balloon Enteroscope for Successful Pancreato-Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography in Patients With Roux-en-Y Gastrectomy: A Comparative Study With Short-Type Double-balloon Enteroscope

短型单气囊小肠镜在Roux-en-Y胃切除术后患者行内镜逆行胆胰管造影术中成功进行胰胆管插管的应用价值:与短型双气囊小肠镜的对比研究

2026-01-210
OAAI
Integrating Epidemiological Investigation and Whole-Genome Sequencing to Evaluate Suspected Healthcare-Associated Transmission of the Corynebacterium jeikeium Complex

整合流行病学调查和全基因组测序以评估凝固酶阴性棒状杆菌复合群的疑似医疗相关传播

2026-01-010
OA
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B

阿特珠单抗联合贝伐珠单抗在Child-Pugh B级肝细胞癌患者中的有效性与安全性

2025-11-280
OAAI
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗后序贯免疫检查点抑制剂再治疗的结局

2025-11-010
OAAI
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

Younossi, Z.M.; de Avila, L.; Petta, S.; Hagström, H.; Kim, S.U.; Nakajima, A.; Crespo, J.; Castera, L.; Alkhouri, N.; Zheng, M.H.; 等. MASLD的纤维化、临床事件及死亡率的预测因素:全球MASLD研究的数据. 肝病学 2025. [Google Scholar] [CrossRef]

2025-11-013
PRE